EP 1141251 A1 20011010 - COMPOUNDS, METHODS OF SCREENING AND METHODS OF TREATMENT FOR CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS
Title (en)
COMPOUNDS, METHODS OF SCREENING AND METHODS OF TREATMENT FOR CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS
Title (de)
VERBINDUNGEN, VERFAHREN DES SCREENINGS UND VERFAHREN DER BEHANDLUNG VON ERKRANKUNGEN DES ZENTRALEN UND PERIPHEREN NERVENSYSTEMS
Title (fr)
COMPOSITIONS, TECHNIQUES DE DEPISTAGE ET METHODES DE TRAITEMENT DE TROUBLES DES SYSTEMES NERVEUX CENTRAL ET PERIPHERIQUE
Publication
Application
Priority
- US 9930806 W 19991222
- US 11362098 P 19981223
- US 32624499 A 19990604
Abstract (en)
[origin: WO0037616A1] The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for treating the pathophysiological effects of head trauma, stroke, ischemia and hypoxia; for treating or protecting from the pathophysiological effects of neurotoxic agents such as ethanol; and for treating neuropsychiatric disorders and central nervous system edema by administering agents that modulate ionic concentrations and/or ionic gradients in the brain, particularly ion-dependent or cation-chloride cotransporter antagonists. Electrolyte cotransport antagonists and combinations of such compositions with other agents for treating various conditions are disclosed. The present invention also relates to methods and compositions for treating pain by administering ion-dependent cotransporter antagonists. Methods and compositions for enhancing cortical function, for example, in centers of cognition, learning and memory, by administering ion-dependant cotransporter agonists are disclosed. Methods and systems for screening drug candidate compounds for desired activities using in vitro and in vivo systems are disclosed.
IPC 1-7
A61K 45/00; A61K 45/06; A61K 31/34; C12M 1/34; G01N 33/483; A61P 25/00
IPC 8 full level
C12M 1/34 (2006.01); A61K 31/00 (2006.01); A61K 31/05 (2006.01); A61K 31/165 (2006.01); A61K 31/17 (2006.01); A61K 31/192 (2006.01); A61K 31/195 (2006.01); A61K 31/196 (2006.01); A61K 31/27 (2006.01); A61K 31/341 (2006.01); A61K 31/357 (2006.01); A61K 31/4015 (2006.01); A61K 31/4166 (2006.01); A61K 31/421 (2006.01); A61K 31/423 (2006.01); A61K 31/4535 (2006.01); A61K 31/513 (2006.01); A61K 31/515 (2006.01); A61K 31/53 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 31/5513 (2006.01); A61K 31/635 (2006.01); A61K 45/00 (2006.01); A61K 45/06 (2006.01); A61P 9/00 (2006.01); A61P 9/02 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 25/00 (2006.01); A61P 25/04 (2006.01); A61P 25/06 (2006.01); A61P 25/08 (2006.01); A61P 25/18 (2006.01); A61P 25/28 (2006.01); A61P 43/00 (2006.01); C12Q 1/02 (2006.01)
CPC (source: EP)
A61K 31/00 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/341 (2013.01); A61K 31/635 (2013.01); A61K 45/06 (2013.01); A61P 9/00 (2017.12); A61P 9/02 (2017.12); A61P 9/10 (2017.12); A61P 9/12 (2017.12); A61P 25/00 (2017.12); A61P 25/04 (2017.12); A61P 25/06 (2017.12); A61P 25/08 (2017.12); A61P 25/18 (2017.12); A61P 25/28 (2017.12); A61P 43/00 (2017.12)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 0037616 A1 20000629; AU 2384500 A 20000712; CA 2356460 A1 20000629; EP 1141251 A1 20011010; EP 1141251 A4 20040922; EP 2332580 A1 20110615; JP 2002533353 A 20021008; JP 2011006438 A 20110113
DOCDB simple family (application)
US 9930806 W 19991222; AU 2384500 A 19991222; CA 2356460 A 19991222; EP 10180060 A 19991222; EP 99967584 A 19991222; JP 2000589672 A 19991222; JP 2010178977 A 20100809